Frontiers in Microbiology, Biotechnology & Crop Science (FMBC)
ISSN: 3139-2741 | Vol. 02, Issue-01, Jan-June, 2026 | pp. 62-80

Optimizing Nanocarrier-Based Ocular Drug Delivery Systems with the Help of Software Design Experts: A Thorough Analysis with Prospects for the Future

D. K Pradhan[1*]

[1]Raigarh College of Pharmacy, Raigarh, Chhattisgarh, India

***Corresponding Author E-mail: dkpradhan74@gmailcom**

Abstract:

In ophthalmology developments in ocular drug delivery systems (ODDS), especially formulations based on nanocarriers, have greatly enhanced treatment results. Notwithstanding these advantages, the creation and refinement of nanocarrier systems entail a complicated interaction between manufacturing factors, formulation variables, and regulatory considerations. Through the integration of computational tools, statistical modeling methodologies, and simulation platforms that improve formulation accuracy, efficiency, and reproducibility, software design specialists have become essential contributors to this process. Using techniques like Quality by Design (QbD), Design of Experiments (DoE), and different factorial and response surface models, this article thoroughly examines the role of software design experts in optimizing nanocarrier-based ODDS. The article also analyzes distribution routes, looks at clinical case studies, and talks about statistical methods like ANOVA and predictive modeling. Prospects for the future are also discussed, such as the application of blockchain, digital twin systems, and artificial intelligence to medication development. In addition to speeding up the medication development process, this interdisciplinary collaboration between software engineering and pharmaceutical sciences guarantees strong regulatory compliance and patient-centered therapeutic results.

Keywords: Software Design, Box–Behnken Design, Optimization, Central Composite Design, Quality by Design, Data Modeling.

Received: Feb. 11, 2026 **Revised: March 21, 2026** **Accepted: April 16, 2026** **Published: June 10, 2026**

DOI:

https://fmbc.nknpub.com/1/issue/archive

1. Introduction

One of the most difficult topics in pharmaceutical research and development is still ocular medication delivery. There are several obstacles to efficient medication delivery because of the eye's distinct structure and physiology, which are intended to safeguard its fragile internal environment. These barriers consist of corneal barriers made by tight connections in the corneal

epithelium, intraocular barriers like the blood-aqueous and blood-retinal barriers, and precorneal restrictions including tear dilution, blinking, and nasolacrimal drainage.Eye drops, suspensions, and ointments are examples of traditional ophthalmic formulations with limited bioavailability; often, less than 5% of the dose can reach the tissues inside the eyes [1-2].

In addition to offering prolonged release and reducing the need for frequent dosage, nanocarriers such as nanoparticles, liposomes, nano emulsions, dendrimers, and nanostructured lipid carriers (NLCs) have demonstrated the capacity to increase drug penetration and get past ocular barriers

Design of Experiments (DoE) and Quality by Design (QbD) Is used to formulate the optimized formulation. Other techniques like central composite, factorial design and Box-Behnken designs are more accurate and effective [3-4]. The use of software design is very advantageous in ocular drug delivery sit requires precise control formulation parameters [5]. Similarly, software designI also maintain the drug release kinetics and their therapeutic valves in the target ocular tissues without systemic leakage [6-7].

Regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are promoting the use of validated software tools for process design, risk assessment, and quality control, which further supports model-based drug development. Software design professionals are adept in complex programming, data analytics, and machine learning techniques, all of which are necessary for the development and upkeep of such digital twins [8-9]. Software plays an equally important role in enhancing the collaboration and knowledge sharing of various teams. Regulatory experts, formulation scientists, process engineers, and clinical researchers usually work alone [10].

Errors are reduced and the development cycle is accelerated by software platforms that include cloud-based data sharing, integrated version control, and real-time collaboration features [11]. Research from both academia and industry has shown in recent years that software design and pharmaceutical formulation may successfully work together. Studies show that the application of DoE techniques leads to faster optimization with fewer experimental runs, resulting in cost savings. Machine learning methods have accurately predicted two crucial formulation factors: particle size distribution and encapsulation efficiency[12]. Simulation platforms have made it possible to examine ocular pharmacokinetics and pharmacodynamics virtually, speeding up the process from bench to bedside.

In ophthalmology, software-based technologies are also enabling individualized medicine. Given patient-specific information, such as teardrop composition, issues with the ocular surface, and genetic markers, algorithms can assist in creating formulations that offer tailored treatment results. Only through the incorporation of cutting-edge computational methods into formulation research will the paradigm change from one-size-fits-all to precision drug delivery be accomplished [13].

A revolutionary era in the delivery of drugs to the eyes is being ushered in by the intersection of software design and pharmaceutical sciences.

The more sophisticated nanocarrier-based systems get, the greater the need for computational modeling, simulation, and automation. Experts in software design are essential collaborators

in the creation of patient-centered, safe, and efficient ophthalmic treatments, not merely supporting players. Their involvement ensures that formulation methods are scientifically sound, statistically sound, and compliant with rules. In addition to being created in labs, the future of ocular drug delivery is also being shaped in code, which is being written by people who are familiar with the languages of machines and molecules [14-15.] Figure 1

Figure 1. Software-Integrated Optimization of Nanocarrier-Based Ocular Drug Delivery Systems



2. Quality by Design (QbD) Implementation in Ocular Drug Development

A methodical, scientific approach to pharmaceutical development, Quality by Design (QbD) requires a thorough understanding of the formulation and production processes [16]. QbD helps discover essential quality characteristics (CQAs) in ocular drug development, including ocular compatibility, drug release patterns, and particle size. (Table 1). Determining CQAs, defining the Quality Target Product Profile (QTPP), and evaluating the risks associated with critical process parameters (CPPs) are the first steps in the process [17]. To map out the influence of numerous variables and create a design space, statistical tools such as DoE are crucial [18-19]. Software solutions such as Design-Expert®, JMP®, and Minitab® facilitate the QbD process by enabling model building, simulation, real-time optimization, and risk assessment. These

tools support regulatory filings by ensuring sound data interpretation and enhanced quality assurance [20,21].

Table 1. Examples for the Design of Experiments (DoE) in Ocular Drug Development Using Nanocarriers

S.No	Formulation/Drug	Type of Design	Observation	Parameters Optimized	Ref.
1	Nanoparticles of timolol-maleate-chitosan	Two-Level Factorial	Increased trapping and particle size	Polymer conc., crosslinker ratio	22
2	LNPs of brimonidine-tartrate	Plackett-Burman	determined the key factors influencing medication release	Screening multiple formulation variables	23
3	Moxifloxacin-loaded Nanostructured-lipd Carriers	Optimization-design	Increased effectiveness of encapsulating	Zeta potential, particle size	24
4	Fluconazole-loaded cubosomes	Three-Level-Factorial	regulated drug release and vesicle size	Surfactant conc., stabilizer, drug ratio	25
5	Nano-structured-lipd Carriersloaded withAzithromycin	Central-Composite-Design	extended medication release with minute discomfort	Lipid-drug ratio, surfactant level	26
6	Ciprofloxacin nano-emulsions	Box–Behnken-Design	The release profile and effective particle size profile	Oil, surfactant, co-surfactant	27

3. Optimizing the Results: Statistical Experiment Design (DoE)

For the purpose of methodically examining how various variables affect desired results, design of experiments, or DoE, is crucial. In systems of ocular nanocarriers, DoE aids in the analysis of the interactions among surfactants, stabilizers, excipients, and medication content. Experts

in software implement optimization algorithms, regression modeling, and graphical visualization tools. (Table 2) [28].

Table 2: Interpretation of Statistical Parameters in Nanocarrier Optimization

S.No	Parameter	Description	Interpretation	Acceptable Criteria	References
1	R^2	variance that the model explains.	shows a good model fit.	≥ 0.8	29
2	Adjusted R^2	R^2 is the number of predictors adjusted.	prevents overfitting of the model	Close to R^2 and ≥ 0.75	30
4	p-value (model)	Overall model significance	The model has statistical significance.	< 0.05	29
5	p-value (Lack of Fit)	check to see if the model fits the data	The model fits the data well.	> 0.05 (non-significant)	31
6	Coefficient of Variation (CV%)	Measurement precision	Reproducibility high	< 10%	30
7	Adequate Precision	Ratio of Signal-to-noise	Model has sufficient signal strength	> 4	30

4.Important Experimental Designs for the Development of Nanocarriers: Comparative Analysis and Illustrative Cases

Choosing and implementing suitable experimental designs is crucial to the development of nanocarrier-based ocular drug delivery systems (ODDS). Selecting the best design has a direct impact on the effectiveness, cost, and precision of formulation development [32]. Each design has a specific function, ranging from variable screening to exact optimization.The fundamental instruments for assessing the impacts and possible interactions of a small number of variables at two levels are two-level factorial designs [33].

For instance, this design was used by Jain et al. [22] (2013) to adjust the crosslinker ratio and polymer concentration in nanoparticles loaded with timolol maleate, greatly improving drug entrapment and particle size homogeneity.

In the initial phases of growth, Plackett–Burman designs are especially useful for identifying important elements among many when several variables may affect outcomes. By using this method, Morsi et al. (2017) [23] established a more focused optimisation. More targeted optimisation by determining crucial elements that influence the release of brimonidine tartrate from lipid nanoparticles.

To fulfil standards of quality, optimisation methods like those in use by Patel et al.24(2014) concentrate on changing a small number of selected variables. Their study of moxifloxacin-loaded nanostructured lipid carriers (NLCs) employed a modified optimization technique to alter zeta potential and particle size in order to improve entrapment and stability. Three-level factorial designs show both the linear and quadratic influences of variables, contribution a more complete understanding than two-level designs. Thakur et al.[25](2018) employed this method to optimize the stabilizer and surfactant concentrations in fluconazole-loaded cubosomes, leading to controlled vesicle size and extended drug release. Central Composite Designs (CCDs) are frequently employed when response surface curvature is expected. These approaches enable accurate modeling of nonlinear relationships. To optimize for extended drug release and less ocular irritation, Parmar et al.[26](2016) used a CCD to balance the surfactant level and lipid-to-drug ratio in azithromycin-loaded NLCs. Compared to CCDs, Box-Behnken Designs offer a more effective way to investigate interactions between three or more variables with fewer experimental runs In Gupta et al. [27] (2020), this technique was 3139-2741 to produce ciprofloxacin nano emulsions, successfully achieving the necessary particle size and release kinetics while minimizing formulation trials. (Table 3). When specific formulation limits exist or component ratios are crucial, alternative experimental designs such as Taguchi, mixed, and D-optimal designs are employed. For example, Ghosh et al. [34] (2015) created minoxidil nano emulsions using a D-optimal combination design, which allows for precise component ratios to anticipate drug release.

Table 3. Comparative Analysis of Statistical Designs Used in Ocular Nanocarrier Optimization

s.no.	Type of design	strength	application	Restriction	References
1	Two-Level Factorial	Easy to use and effective for a limited set of parameters	Initial formulation variable screening	Unable to identify curvature in answers	35
2	Plackett–Burman (PBD)	Effective at filtering a variety of factors	Finding the important variables	disregards quadratic effects and interactions	36
3	Three-Level Factorial	examines interaction, linear, and quadratic effects.	Critical parameter optimization	More runs are needed than with two-level designs.	37
4	Central Composite Design	Ideal for curvature estimates and intricate modeling	Optimization of advanced formulations	can grow significantly with numerous conditions.	38
5	Box–Behnken Design	superior for quadratic models and requires less runs.	Final validation and optimization	Unsuitable for investigation outside of the design space	39

5. Statistical Analysis of Different Experimental Designs in Ocular Nanocarrier Systems

To create reliable ocular nanocarrier systems, formulation variables must be identified, examined, and optimized by statistical experimental techniques. The integration of software systems enables researchers to precisely model interactions, predict outcomes, and validate formulations. Below is a summary of common statistical designs and how they are used in the delivery of ophthalmic medications [35].

1. Two-Level Factorial Design – When resources are scarce, it works well for initial research since it can assess the main, and interaction impacts of a small number of variables.

2. Plackett–Burman

Design (PBD), which ignores interaction effects, is useful for identifying key factors by screening a large number of them.

3. Three-Level Factorial Design – Allows comprehension of linear, quadratic, as well as interaction effects, important when studying deeper response surfaces.

4. Central Composite Design (CCD) – Building second order (quadratic) models is accomplished with Central Composite Design (CCD), which works well with response surface methodology (RSM).

5. Box–Behnken Design (BBD) – Analysis of Variance (ANOVA) and Response Surface Methodology (RSM) are two of the most widely used statistical analysis techniques in the design and optimization of nanocarrier-based ocular drug delivery systems. One type of RSM design that efficiently explores quadratic response surfaces while requiring fewer runs than CCD. (Table 4). ANOVA tests p-values and F-values to assess the significance of model terms and interactions. The factor has a substantial impact on the response if the p-value is less than 0.05. Stronger effects are indicated by higher F-values, which compare model variance to residual variance [36]. The model's goodness-of-fit is indicated by the coefficient of determination (R2), where values nearer to indicate higher model accuracy. This is further refined by modified R^2 which mitigates the risk of overfitting by accounting for the number of variables. Tests for lack of fit assess whether the model sufficiently represents the experimental data. RSM predicts factor interactions and optimizes responses using polynomial equations which are usually quadratic. The use of contour plots and 3D surface plots facilitates understanding complex variable interactions & finding optimal formulation conditions [37].

Table 4: Comparative Statistics for Ocular Nanocarrier Development Experimental Designs

S.No.	Design Type	Number of Factors	Statistical	Number of Runs	Model Complexity	Features
1	Full Factorial	2–5	High R^2, significant F-values,	2^k (exponential growth)	High (main + interactions)	detailed interaction analysis

2	Fractional Factorial	Up to 10	Efficient screening, moderate R^2,	Fraction of 2^k	Reduced interaction	potential confounding
3	Plackett-Burman	Many (>10)	$p<0.05$ highlights key factors	Multiples of 4	Screening only	Identifies main effects,
4	Central Composite Design (CCD)	3-6	significant quadratic terms,	15–30 High R^2 & Adjusted R^2,	Quadratic model	valid lack of fit
5	Box-Behnken Design	3–7	Efficient quadratic model	13–27	Quadratic model	good prediction accuracy

7. Data Analysis and Model Application

Software experts employ predictive modeling, multivariate regression & ANOVA to forecast performance and validate experimental results. The incorporation of machine learning algorithms facilitates regulatory preparation, continuous process verification & scale-up prediction.

The development & enhancement of ocular drug delivery systems (ODDS) based on nanocarriers depend heavily on data analysis [38]. Interpretation, modeling & validation must be done methodically due to the intricate interactions among formulation variables, process parameters and product quality factors. Software design specialists are crucial to this process as they develop, integrate& manage complex computational systems that transform raw experimental data into valuable insights [39].The two most often used analytical techniques for figuring out how independent variables like zeta potential, drug encapsulation effectiveness, particle size and release kinetics are analysis of variance (ANOVA) and multivariate regression analysis.

These statistical methods are often implemented using software platforms such as Design-Expert®, JMP®, Minitab®, and R. Experts in software ensure that the appropriate model is selected, that data entry protocols are adhered to, and that visualization results are generated. By creating specialized scripts and automation processes, software specialists help pharmaceutical scientists conduct high-throughput, scalable, and repeatable investigations.

Understanding and predicting the behavior of nanocarriers under diverse physiological settings is made possible in large part by predictive modeling. Software experts create and improve algorithms that utilize both historical data and recent experimental findings to predict

formulation performance [40]. These models help define the design space and optimize the process parameters inside Quality by Design (QbD) frameworks, while also aiding early-stage screening.

The incorporation of machine learning techniques such as neural networks, support vector machines and decision trees into drug development processes has been facilitated by the increasing accessibility of formulation and clinical data [41]. Software design specialists contribute by selecting datasets, developing models, testing results, and incorporating predictive tools into user-friendly interfaces. These techniques provide more accurate predictions of inter-batch variability, long-term stability, and in vivo performance. Software engineers are contributing to the development of real-time data collection and process monitoring systems. Continuous process verification provided by these technologies is crucial for maintaining consistency in large scale manufacturing [42]. Researchers may quickly spot anomalies, enhance algorithms in real time due to customized dashboard that effectively display critical data patterns. Collaboration between pharmaceutical scientists, software design experts enhance the precision & reliability of data processing in ODDS research. Collectively, they generate more dependable formulations, expedited development timelines & data-informed decisions that comply with scientific and regulatory standards [43].

5. Clinical Research Using Ocular Drug Delivery Systems Based on Nanocarriers

Ocular drug delivery systems utilizing nanocarriers clinical validation has demonstrated enhancements in safety, efficacy & patient compliance. Quality by Design & Experiments are utilized to develop various formulation [44.]

DoE approaches have proved the value of software-assisted Optimisation by shifting from laboratory to clinical applications. Ikervis® is a cationic nano emulsion containing cyclosporine A, which has received licensing in Europe for the treatment of dry eye disease [45]. The formulation cationic nature improves electrostatic interactions with the negatively charged ocular surface, cutting down on the number of administrations required. Latanoprost loaded nanocarriers enhanced IOP control in glaucoma patients [46]. Lipid based nanocarriers enhanced corneal penetration and facilitated sustained drug release thereby reducing dosing frequency & minimizing side effects linked to peak medication concentrations [47]. Kumari S et al. (2021) assessed dexamethasone-loaded solid lipid nanoparticles in a clinical context, demonstrating favorable pharmacokinetic outcomes characterised by enhanced ocular tissue targeting and reduced systemic absorption. This reduces the likelihood of adverse systemic effects while maintaining effective intraocular anti-inflammatory action, crucial for chronic ocular inflammation & post-surgical recovery. Hybrid nanocarriers, stimuli-responsive systems & gene-delivery platforms are currently under investigation in new clinical trials [48,49.]

6. Comparison of Therapeutic Outcomes in Different Delivery Systems

The success of these systems depends on the anatomical & physiological challenges of each route as well as drug pharmacokinetics, necessitating software-aided design change.

6.1Nasal Delivery

Chitosan-coated NLCs can be intranasally administered via the olfactory route avoiding the blood brain barrier. Software modeling has been utilized to precisely determine particle size, mucoadhesive, zeta potential, enhancing therapy outcomes for retinal neurodegenerative disorders [50].

6.2 Oral Delivery

Oral administration of labile and weakly permeable medications is still difficult, even with recent advancements in formulation and delivery system designs. Although systemic methods have significant issues with ocular bioavailability, CCD optimized lipid-based carriers enhance lymphatic absorption & prolonged release. Without resulting in systemic adverse effects. These designs ensure that adequate medication levels reach ocular tissues [51].

6.3Mucoadhesive Delivery

Factorial-created in situ gelling devices offer sustained drug release & extended precorneal residency. Software-assisted optimization which predicts gelation temperature, polymer concentration, pH accessibility, guarantees high treatment efficacy & patient adherence [52].

6.4Topical Delivery

Topical nano emulsions such as Ikervis® benefit greatly from the use of QbD and DoE methods (Table 6). The optimal droplet size, stability & surface charge are ensured by these methods, improving bioavailability, lowering pain & increasing patient compliance. Each route emphasizes the importance of employing innovative design strategies that encompass pharmaceutical objectives, patient requirements and route specific challenges. Software design experts utilize predictive modelling, real-time simulation and data analytics integration to enhance optimization [53].

Table 6. Summary of Delivery Routes, Design Tools, and Optimization Outcomes

S.no	Delivery Route	Drug/Formulation	Design Tool	Optimization Outcome
1	Nasal Chitosan	Chitosan coated NLCs	Box–Behnken	Enhanced brain delivery, permeation
2	Oral	Lipid based ocular drug	Central Composite Design|	Increased bioavailability, extended release
3	Mucoadhesive	Fluconazole in situ gel	Factorial Design	Improved ocular retention efficacy
4	Topical	Cyclosporine nano emulsion	QbD + DoE	High corneal penetration, patient compliance

8. Future Perspectives

Software design specialists are not only advantageous but also necessary for pharmaceutical research as the complexity of nanocarrier-based ocular drug delivery systems (ODDS) rises. The future of ocular therapeutics depends on the fusion of advanced computational technology and experimental science, in which software programmers will remain essential [54].

software design is used to develop different techniques that can evaluate different research investigations and untested link between formulation parameters, critical quality attributes (CQAs), and treatment results. The possible changes in, polymer concentrations, surfactant concentrations or particle sizes on drug release as well as bioavailability can be estimate using these models. These techniques decrease the number of trial-and-error that can be used in formulation development [55].

The development of integrated modeling systems employing commercial products like Simcyp® and GastroPlus®, Python-based frameworks, and software like MATLAB is another important breakthrough. These systems enable the use of actual physiological variables to model the distribution, degradation, and absorption of ocular drugs. Software developers have created specialized modules for ocular pharmacokinetics to help pharmaceutical scientists evaluate formulations virtually before doing actual laboratory testing [56]. Virtual formulation labs that are powered by software interfaces are growing in popularity. By giving formulation scientists simple dashboards to enter variables & rapidly evaluate simulated results these systems save time & materials. These digital environments are developed by software professionals who also guarantee that they satisfy regulatory standard for integrity of data & validating models. Software developers are enhancing production processes such as emulsification, lyophilization and sterilization, which are crucial for maintaining the stability & sterility of ophthalmic nanocarriers through the development of digital process control and automation systems [57]. Automated systems guarantee consistent product quality by monitoring critical process parameters with artificial intelligence (AI) algorithms, data logging software and real-time sensors.

Moreover, interdisciplinary teams comprising software developers, clinical researchers, and formulation scientists can exchange real-time data, monitor progress, and enhance development methodologies through cloud-based collaboration tools. This collaborative environment fosters innovation & ongoing enhancement [58].

The integration of augmented reality with interactive data visualisation tool created by software designers may boost future decision making. These technologies assist researchers in visualizing formulation behaviors in three dimensions, simulating in vivo drug performance and intuitively understanding complex dataset. The endeavours of software design experts will shape the future of nanocarrier based ODDS [59]. Pharmaceutical research will achieve unprecedented levels of accuracy, efficacy and innovation due to advancements in predictive modelling platforms, automation systems, and intelligent design tools [60].

9. Conclusion

The development of nanocarrier-based ocular medication delivery systems necessitates a comprehensive interdisciplinary approach alongside pharmacological proficiency. The advancement of computational tools, statistical frameworks and predictive models that enhance formulation precision, process reliability, and clinical efficacy has rendered software design professional important contributors in this domain. They can develop products systematically, consistently, and efficiently by employing Quality by Design (QbD), Design of Experiments (DoE) and advanced modelling tools. These instruments facilitate scalable manufacturing

methods, optimize formulation parameter & simplify regulatory adherence. As the intricacy of ocular drug delivery systems escalates, coordination between software engineer & pharmaceutical expert will become increasingly vital. This association will accelerate the development of next-generation, patient-safe, and effective pharmaceuticals, while also promoting innovation and improving patient outcomes. This interdisciplinary collaboration, integrating data, design, and clinical expertise, is pivotal for the future of ocular drug delivery.

Reference:

1. Bachu, R. D., Chowdhury, P., Al-Saedi, Z. H. F., Karla, P. K., & Boddu, S. H. S. (2018). Ocular drug delivery barriers: Role of nanocarriers in the treatment of anterior segment ocular diseases. *Pharmaceutics, 10*(1), 28. https://doi.org/10.3390/pharmaceutics10010028

2. Khan, S., Sharma, A., & Jain, V. (2023). An overview of nanostructured lipid carriers and its application in drug delivery through different routes. *Advanced Pharmaceutical Bulletin, 13*(3), 446–460. https://doi.org/10.34172/apb.2023.056

3. Li, S., Chen, L., & Fu, Y. (2023). Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects. *Journal of Nanobiotechnology, 21*(1), 232. https://doi.org/10.1186/s12951-023-01992-2

4. Witika, B. A., Poka, M. S., Demana, P. H., Matafwali, S. K., Melamane, S., Khamanga, S. M., & Makoni, P. A. (2022). Lipid-based nanocarriers for neurological disorders: A review of the state-of-the-art and therapeutic success to date. *Pharmaceutics, 14*(4), 836. https://doi.org/10.3390/pharmaceutics14040836

5. Alshaer, W., Nsairat, H., Lafi, Z., Hourani, O. M., Al-Kadash, A., Esawi, E., & Alkilany, A. M. (2022). Quality by design approach in liposomal formulations: Robust product development. *Molecules, 28*(1), 10. https://doi.org/10.3390/molecules28010010

6. Yu, L. X., Amidon, G., Khan, M. A., Hoag, S. W., Polli, J., Raju, G. K., & Woodcock, J. (2014). Understanding pharmaceutical quality by design. *The AAPS Journal, 16*(4), 771–783. https://doi.org/10.1208/s12248-014-9598-3

7. Rojekar, S., Parit, S., Gholap, A. D., Manchare, A., Nangare, S. N., Hatvate, N., Sugandhi, V. V., Paudel, K. R., & Ingle, R. G. (2024). Revolutionizing eye care: Exploring the potential of microneedle drug delivery. *Pharmaceutics, 16*(11), 1398. https://doi.org/10.3390/pharmaceutics16111398

8. Souto, E. B., Dias-Ferreira, J., López-Machado, A., Ettcheto, M., Cano, A., Camins, A., Espina, M., Garcia, M. L., & Sánchez-López, E. (2019). Advanced formulation approaches for ocular drug delivery: State-of-the-art and recent patents. *Pharmaceutics, 11*(9), 460. https://doi.org/10.3390/pharmaceutics11090460

9. Botín-Sanabria, D. M., Mihaita, A.-S., Peimbert-García, R. E., Ramírez-Moreno, M. A., Ramírez-Mendoza, R. A., & Lozoya-Santos, J. J. (2022). Digital twin technology challenges and applications: A comprehensive review. *Remote Sensing, 14*(6), 1335. https://doi.org/10.3390/rs14061335

10. Botín-Sanabria, D. M., Mihaita, A.-S., Peimbert-García, R. E., Ramírez-Moreno, M. A., Ramírez-Mendoza, R. A., & Lozoya-Santos, J. J. (2022). Digital twin technology challenges and applications: A comprehensive review. *Remote Sensing, 14*(6), 1335. https://doi.org/10.3390/rs14061335

11. Chen, Y., Yang, O., Sampat, C., Bhalode, P., Ramachandran, R., & Ierapetritou, M. (2020). Digital twins in pharmaceutical and biopharmaceutical manufacturing: A literature review. *Processes, 8*(9), 1088. https://doi.org/10.3390/pr8091088

12. Sachdeva, S., Bhatia, S., Al Harrasi, A., Shah, Y. A., Anwer, K., Philip, A. K., Shah, S. F. A., Khan, A., & Halim, S. A. (2024). Unraveling the role of cloud computing in health care system and biomedical sciences. *Heliyon, 10*(7), e29044. https://doi.org/10.1016/j.heliyon.2024.e29044

13. Al-Kharusi, G., Dunne, N. J., Little, S., & Levingstone, T. J. (2022). The role of machine learning and design of experiments in the advancement of biomaterial and tissue engineering research. *Bioengineering, 9*(10), 561. https://doi.org/10.3390/bioengineering9100561

14. Patel, A., Cholkar, K., Agrahari, V., & Mitra, A. K. (2013). Ocular drug delivery systems: An overview. *World Journal of Pharmacology, 2*(2), 47–64. https://doi.org/10.5497/wjp.v2.i2.47

15. Liu, L.-C., Chen, Y.-H., & Lu, D.-W. (2023). Overview of recent advances in nano-based ocular drug delivery. *International Journal of Molecular Sciences, 24*(20), 15352. https://doi.org/10.3390/ijms242015352

16. Vipanchi, V., Fatima, M., & Domaraju, P. (2023). Quality by design approach for nanosystem-based topical drug delivery. *German Journal of Pharmaceutics and Biomaterials, 2*, 1–17. https://doi.org/10.5530/gjpb.2023.1.1

17. Yu, L. X. (2008). Pharmaceutical quality by design: Product and process development, understanding, and control. *Pharmaceutical Research, 25*, 781–791. https://doi.org/10.1007/s11095-007-9511-1

18. Holm, P., Allesø, M., Bryder, M. C., & Holm, R. (2017). Q8 (R2) pharmaceutical development. In *ICH quality guidelines: An implementation guide* (pp. 535–577). ICH.

19. Rapalli, V. K., Khosa, A., Singhvi, G., Girdhar, V., Jain, R., & Dubey, S. K. (2019). Application of QbD principles in nanocarrier-based drug delivery systems. In *Pharmaceutical quality by design: Principles and applications* (pp. 255–296). Academic Press.

20. Quality by design for biotech, pharmaceutical and medical devices. (2023). *QbD case study—ACE tablets—QTPP, CQA, CPP, CMA*. Retrieved September 10, 2023, from [URL if available]

21. Amasya, G., Aksu, B., Badilli, U., Onay-Besikci, A., & Tarimci, N. (2019). QbD-guided early pharmaceutical development study: Production of lipid nanoparticles by high-pressure homogenization for skin cancer treatment. *International Journal of Pharmaceutics, 563*, 110–121. https://doi.org/10.1016/j.ijpharm.2019.03.056

22. Jain, D., et al. (2013). Formulation and evaluation of chitosan nanoparticles for ophthalmic delivery of timolol maleate. *Scientific Reports.*

23. Morsi, N. M., et al. (2017). Lipid nanoparticles for ocular delivery of brimonidine tartrate: Formulation and in vivo evaluation. *European Journal of Pharmaceutics and Biopharmaceutics.*

24. Patel, A., et al. (2014). Formulation and optimization of moxifloxacin hydrochloride-loaded NLCs for ophthalmic application. *AAPS PharmSciTech.*

25. Thakur, R. R., et al. (2018). Cubosome-based delivery of fluconazole for ocular therapy: Formulation optimization using three-level factorial design. *Drug Development and Industrial Pharmacy.*

26. Parmar, P. K., et al. (2016). Central composite design for development of azithromycin-loaded NLCs for ocular delivery. *Pharmaceutical Development and Technology.*

27. Gupta, M., et al. (2020). Nanoemulsion-based delivery system of ciprofloxacin for ocular application using Box–Behnken design. *International Journal of Pharmaceutics.*

28. Rampado, R., & Peer, D. (2023). Design of experiments in the optimization of nanoparticle-based drug delivery systems. *Journal of Controlled Release, 358*, 398–419. https://doi.org/10.1016/j.jconrel.2023.05.001

29. Montgomery, D. C. (2017). *Design and analysis of experiments* (8th ed.). John Wiley & Sons.

30. Myers, C. E., Kostek, J. A., Ekeh, B., Sanchez, R., Ebanks-Williams, Y., Krusznis, A., et al. (2016). Watch what I do, not what I say I do: Computer-based avatars to assess behavioral

inhibition, a vulnerability factor for anxiety disorders. *Computers in Human Behavior, 55*, 804–816.

31. Box, G. E. P., Hunter, J. S., & Hunter, W. G. (2005). *Statistics for experimenters: Design, innovation, and discovery* (2nd ed.). Wiley.

32. Li, S., Chen, L., & Fu, Y. (2023). Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects. *Journal of Nanobiotechnology, 21*(1), 232. https://doi.org/10.1186/s12951-023-01992-2

33. Moon, S., Saboe, A., & Smanski, M. J. (2024). Using design of experiments to guide genetic optimization of engineered metabolic pathways. *Journal of Industrial Microbiology & Biotechnology, 51*, kuae010. https://doi.org/10.1093/jimb/kuae010

34. Ghosh, A., et al. (2015). Development of minoxidil nanoemulsion using D-optimal mixture design for ocular delivery. *Colloids and Surfaces B: Biointerfaces.*

35. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics, 15*(7), 1916. https://doi.org/10.3390/pharmaceutics15071916

36. Kim, T. K. (2017). Understanding one-way ANOVA using conceptual figures. *Korean Journal of Anesthesiology, 70*(1), 22–26. https://doi.org/10.4097/kjae.2017.70.1.22

37. Kim, T. K. (2015). T test as a parametric statistic. *Korean Journal of Anesthesiology, 68*, 540–546. https://doi.org/10.4097/kjae.2015.68.6.540

38. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery, 18*(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5

39. Amrutkar, C. S., & Patil, S. B. (2023). Nanocarriers for ocular drug delivery: Recent advances and future opportunities. *Indian Journal of Ophthalmology, 71*(6), 2355–2366. https://doi.org/10.4103/ijo.IJO_1893_22

40. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. *Drug Discovery Today, 26*, 80–93. https://doi.org/10.1016/j.drudis.2020.10.010

41. Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022). Machine learning in drug discovery: A review. *Artificial Intelligence Review, 55*, 1947–1999. https://doi.org/10.1007/s10462-021-10058-4

42. Kim, E. J., Kim, J. H., Kim, M. S., Jeong, S. H., & Choi, D. H. (2021). Process analytical technology tools for monitoring pharmaceutical unit operations: A control strategy for continuous process verification. *Pharmaceutics, 13*(6), 919. https://doi.org/10.3390/pharmaceutics13060919

43. Khadela, A., Popat, S., Ajabiya, J., Valu, D., Savale, S., & Chavda, V. P. (2023). AI, ML and other bioinformatics tools for preclinical and clinical development of drug products. In *Bioinformatics tools for pharmaceutical drug product development* (pp. 255–284). Wiley.

44. Gaudana, R., Jwala, J., Boddu, S. H., & Mitra, A. K. (2009). Recent perspectives in ocular drug delivery. *Pharmaceutical Research, 26*, 1197–1216. https://doi.org/10.1007/s11095-008-9694-0

45. Pisella, P. J., Labetoulle, M., Doan, S., Cochener-Lamard, B., Amrane, M., Ismail, D., Creuzot-Garcher, C., & Baudouin, C. (2018). Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: Experience through the French early-access program. *Clinical Ophthalmology, 12*, 289–299. https://doi.org/10.2147/OPTH.S150957

46. Iqbal, H., Razzaq, A., Zhou, D., Lou, J., Xiao, R., Lin, F., & Liang, Y. (2024). Nanomedicine in glaucoma treatment: Current challenges and future perspectives. *Materials Today Bio, 28*, 101229. https://doi.org/10.1016/j.mtbio.2024.101229

47. Navarro-Partida, J., Castro-Castaneda, C. R., Santa Cruz-Pavlovich, F. J., Aceves-Franco, L. A., Guy, T. O., & Santos, A. (2021). Lipid-based nanocarriers as topical drug delivery systems for intraocular diseases. *Pharmaceutics, 13*(5), 678. https://doi.org/10.3390/pharmaceutics13050678

48. Kumari, S., Dandamudi, M., Rani, S., Behaeghel, E., Behl, G., Kent, D., O'Reilly, N. J., O'Donovan, O., McLoughlin, P., & Fitzhenry, L. (2021). Dexamethasone-loaded nanostructured lipid carriers for the treatment of dry eye disease. *Pharmaceutics, 13*(6), 905. https://doi.org/10.3390/pharmaceutics13060905

49. Müller, R. H., & Junghanns, J. U. A. H. (2008). Nanocrystal technology, drug delivery and clinical applications. *International Journal of Nanomedicine, 3*, 295–310. https://doi.org/10.2147/IJN.S595

50. Omidian, H., Gill, E. J., Dey Chowdhury, S., & Cubeddu, L. X. (2024). Chitosan nanoparticles for intranasal drug delivery. *Pharmaceutics, 16*(6), 746. https://doi.org/10.3390/pharmaceutics16060746

51. Zhang, Z., Lu, Y., Qi, J., & Wu, W. (2021). An update on oral drug delivery via intestinal lymphatic transport. *Acta Pharmaceutica Sinica B, 11*(8), 2449–2468. https://doi.org/10.1016/j.apsb.2020.12.022

52. Szalai, B., Jójárt-Laczkovich, O., Kovács, A., Berkó, S., Balogh, G. T., Katona, G., & Budai-Szűcs, M. (2022). Design and optimization of in situ gelling mucoadhesive eye drops containing dexamethasone. *Gels, 8*(9), 561. https://doi.org/10.3390/gels8090561

53. Preeti, Sambhakar, S., Malik, R., Bhatia, S., Al Harrasi, A., Rani, C., Saharan, R., Kumar, S., Geeta, & Sehrawat, R. (2023). Nanoemulsion: An emerging novel technology for improving the bioavailability of drugs. *Scientifica, 2023*, 6640103. https://doi.org/10.1155/2023/6640103

54. Whalen, M., Akula, M., McNamee, S. M., DeAngelis, M. M., & Haider, N. B. (2024). Seeing the future: A review of ocular therapy. *Bioengineering, 11*, 179. https://doi.org/10.3390/bioengineering11020179

55. Pokhrel, D. R., Sah, M. K., Gautam, B., Basak, H. K., Bhattarai, A., & Chatterjee, A. (2023). A recent overview of surfactant–drug interactions and their importance. *RSC Advances, 13*(26), 17685–17704. https://doi.org/10.1039/d3ra02883f

56. Cabrera, F. J., Wang, D. C., Reddy, K., Acharya, G., & Shin, C. S. (2019). Challenges and opportunities for drug delivery to the posterior of the eye. *Drug Discovery Today, 24*(8), 1679–1684. https://doi.org/10.1016/j.drudis.2019.05.035

57. Gawin-Mikołajewicz, A., Nartowski, K. P., Dyba, A. J., Gołkowska, A. M., Malec, K., & Karolewicz, B. (2021). Ophthalmic nanoemulsions: From composition to technological processes and quality control. *Molecular Pharmaceutics, 18*(10), 3719–3740. https://doi.org/10.1021/acs.molpharmaceut.1c00650

58. VanWormer, A., Lindquist, R., Robiner, W., & Finkelstein, S. (2012). Interdisciplinary collaboration 3139-2741 to clinical research: An example of remote monitoring in lung transplantation. *Dimensions of Critical Care Nursing, 31*(3), 202–210. https://doi.org/10.1097/DCC.0b013e31824e0307

59. Parvin, N., Joo, S. W., Jung, J. H., & Mandal, T. K. (2025). Multimodal AI in biomedicine: Pioneering the future of biomaterials, diagnostics, and personalized healthcare. *Nanomaterials, 15*, 895. https://doi.org/10.3390/nano15120895

60. Karalis, V. D. (2024). The integration of artificial intelligence into clinical practice. *Applied Biosciences, 3*, 14–44. https://doi.org/10.3390/applbiosci3010002